Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Discontinuation follows a halt in new patient enrollment to A4021016 in September 2009
Subscribe to our email newsletter
Pfizer has discontinued A4021016 (also known as ADVIGO 1016), a phase 3 trial examining the effects of investigational compound, Figitumumab (CP-751,871), due to the study meeting predefined boundaries for early termination. The compound was being studied as first-line treatment in patients with advanced non-adenocarcinoma non-small cell lung cancer (NSCLC).
Reportedly, an analysis by Data Safety Monitoring Committee (DSMC) showed that the addition of Figitumumab to Paclitaxel plus Carboplatin would be unlikely to meet the primary endpoint of improving overall survival compared to Paclitaxel plus Carboplatin alone.
The discontinuation follows a halt in new patient enrollment to A4021016 in September 2009, when the DSMC observed an apparent imbalance of certain serious adverse events between the treatment arms with more events, including fatalities, occurring in patients who were randomised to receive figitumumab.
The phase 3 study was initiated based on findings from a phase 2 study that identified patients of squamous cell histology, and a disease with a high unmet medical need, as those who could potentially benefit most from Figitumumab treatment.
Mace Rothenberg, senior vice president of clinical development and medical affairs for oncology business unit at Pfizer, said: “While these findings are disappointing, Pfizer is committed to using information gained from this study to refine the design of future trials of figitumumab in non-small cell lung cancer. We are hopeful that we will be able to identify a subset of patients who may have derived benefit from the addition of figitumumab to chemotherapy. If this can be done, then future trials will focus on this group of patients in our efforts to deliver this drug to the right patient.”
The company has notified A4021016 clinical investigators and has initiated the notification procedure for all involved regulatory agencies of the discontinuation of A4021016. Investigators have been instructed to work with all of their patients in the A4021016 study on an individual basis to determine an appropriate course of action.
A4021016 is part of a global phase 3 clinical trial program, called ADVIGO (ADVancing IGF-1R in Oncology), which is studying figitumumab in patients with NSCLC. The program also includes A4021018 (also known as ADVIGO 1018), an ongoing study in patients with refractory advanced non-adenocarcinoma NSCLC that is evaluating Figitumumab with Erlotinib compared to Erlotinib alone.
A4021017 (also known as ADVIGO 1017) is a phase 3 trial that will evaluate Figitumumab in combination with another chemotherapy regimen, Cisplatin and Gemcitabine, as 1st-line treatment of advanced NSCLC. The trial is still in the planning stage and will incorporate lessons learned from ADVIGO 1016 into the final design.
In addition to NSCLC, Pfizer is studying Figitumumab in clinical trials for the potential treatment of other cancers, including prostate and breast cancers, and Ewing’s sarcoma.